Literature DB >> 6099693

Effects of auranofin on leukotriene production and leukotriene stimulated neutrophil function.

I Hafström, B Ringertz, J Palmblad, C Malmsten.   

Abstract

Arachidonic acid is metabolized in neutrophils by lipoxygenase to leukotrienes, which are suggested to play a central role in inflammation. The antirheumatic drug auranofin (4 micrograms/ml) was found not to inhibit neutrophil production of the lipoxygenase products 5-HETE-, 15-HETE and LTB4, in vitro when stimulated with the calcium ionophore A23187. Auranofin, however, modulated neutrophil aggregation, enzyme release and chemotaxis induced by LTB4. The results suggest that auranofin may exert some of its antirheumatic effects through affecting neutrophil responses to leukotrienes.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6099693     DOI： 10.1007/bf01966773

Source DB:  PubMed          Journal:  Agents Actions        ISSN： 0065-4299


  34 in total

1.  The urinary excretion of lysozyme in dogs.

Authors:  J F Harrison; A D Barnes
Journal:  Clin Sci       Date:  1970-04       Impact factor: 6.124

2.  Leukotriene B4--a stereospecific stimulator for release of lysosomal enzymes from neutrophils.

Authors:  I Hafstrom; J Palmblad; C L Malmsten; O Rådmark; B Samuelsson
Journal:  FEBS Lett       Date:  1981-07-20       Impact factor: 4.124

3.  Modulation of neutrophil functions by auranofin. Studies on effects in vitro and in rheumatoid arthritis patients.

Authors:  I Hafström; A M Udén; J Palmblad
Journal:  Scand J Rheumatol       Date:  1983       Impact factor: 3.641

4.  Leukotriene-induced neutrophil aggregation in vitro.

Authors:  B Ringertz; J Palmblad; O Rådmark; C Malmsten
Journal:  FEBS Lett       Date:  1982-10-18       Impact factor: 4.124

5.  Effect of auranofin, a new antiarthritic agent, on immune complex-induced release of lysosomal enzymes from human leukocytes.

Authors:  A E Finkelstein; F R Roisman; D T Walz
Journal:  Inflammation       Date:  1977-06       Impact factor: 4.092

6.  Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187.

Authors:  P Borgeat; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1979-05       Impact factor: 11.205

7.  Arachidonic acid metabolism in polymorphonuclear leukocytes: unstable intermediate in formation of dihydroxy acids.

Authors:  P Borgeat; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

8.  Effects of gold compounds on the function of phagocytic cells. II. Inhibition of superoxide radical generation by tripeptide-activated polymorphonuclear leukocytes.

Authors:  P Davis; C Johnston; C L Miller; K Wong
Journal:  Arthritis Rheum       Date:  1983-01

9.  Metabolism of arachidonic acid in polymorphonuclear leukocytes. Structural analysis of novel hydroxylated compounds.

Authors:  P Borgeat; B Samuelsson
Journal:  J Biol Chem       Date:  1979-08-25       Impact factor: 5.157

10.  Effects of gold compounds on the function of phagocytic cells. I. Suppression of phagocytosis and the generation of chemiluminescence by polymorphonuclear leukocytes.

Authors:  P Davis; C L Miller; A S Russell
Journal:  J Rheumatol Suppl       Date:  1982 Jul-Aug
View more
  4 in total

1.  Effect of auranofin on eicosanoids and protein kinase C in human neutrophils.

Authors:  T Herlin; K Fogh; N O Christiansen; K Kragballe
Journal:  Agents Actions       Date:  1989-08

2.  Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia.

Authors:  Vemparala Subbarayan; Xiao-Chun Xu; Jeri Kim; Peiying Yang; Ashraful Hoque; Anita L Sabichi; Norma Llansa; Gabriella Mendoza; Christopher J Logothetis; Robert A Newman; Scott M Lippman; David G Menter
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

3.  Anti-inflammatory drugs modulate histamine release from mast cells induced by fibrinogen degradation products.

Authors:  E Wojtecka-Lukasik; J Stachurska; M Kopeć; S Maśliński
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

4.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.